Posted by Michael Wonder on 01 Aug 2022
Stelara (ustekinumab) approved by the U.S. FDA to treat paediatric patients with active psoriatic arthritis
1 August 2022 - As the first and only biologic targeting both cytokines interleukin-12 and interleukin-23, Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA has approved Stelara (ustekinumab) for the treatment of paediatric patients six years of age and older with active psoriatic arthritis.
